Navigating the Biosimilar Landscape: What to watch out in 2024 and Beyond
The anticipated expiration of exclusivity rights for major biologics in 2022…
The Next Frontier: Pharma and Longevity
From The Epic of Gilgamesh, the earliest surviving book, to the controversial…
Do you want to gain insights into the CVC portfolios of 19 Biopharma Companies and Google? Then read below!
Over the past few years, corporate venture capital (CVC) companies backed by or…
How Gene Therapy sponsors can overcome regulatory approval bottlenecks.
In a previous article, we discussed the findings of a Linkedin poll regarding…
What a Linkedin poll revealed about the Gene Therapy challenges.
With over 2 million groups where professionals from various industries network,…
